Vimarsana
Biggest News Aggregation in the World

Page 20 - Beigene News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Beigene. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Beigene Today - Breaking & Trending Today

BeiGene Receives New Approvals for BRUKINSA® (zanubrutinib) in China - Vimarsana News

BeiGene Receives New Approvals for BRUKINSA® (zanubrutinib) in China

BRUKINSA is approved for first-line treatment for CLL/SLL and WM in China and has multiple approved indications in more than 65 markets worldwide ... | May 6, 2023

BeiGene (NASDAQ:BGNE) Issues Quarterly Earnings Results - Vimarsana News

BeiGene (NASDAQ:BGNE) Issues Quarterly Earnings Results

BeiGene (NASDAQ:BGNE – Get Rating) posted its earnings results on Thursday. The company reported ($3.34) earnings per share for the quarter, topping the consensus estimate of ($3.66) by $0.32, Briefing.com reports. The firm had revenue of $447.80 million for the quarter, compared to analyst estimates of $449.44 million. BeiGene had a negative return on equity […]

Source: wkrb13.com
BeiGene, Ltd.: BeiGene Reports First Quarter 2023 Financial Results and Corporate Developments - Vimarsana News

BeiGene, Ltd.: BeiGene Reports First Quarter 2023 Financial Results and Corporate Developments

Recorded first quarter product revenue of $410.3 million, increasing 56.9% over $261.6 million from the prior-year period Launched BRUKINSA in the U.S. for adult patients with chronic lymphocytic

BeiGene Reports First Quarter 2023 Financial Results and Corporate Developments - Vimarsana News

BeiGene Reports First Quarter 2023 Financial Results and Corporate Developments

Recorded first quarter product revenue of $410.3 million, increasing 56.9% over $261.6 million from the prior-year period Launched BRUKINSA® in the U.S. for adult patients with chronic... | May 4, 2023

Immix Biopharma Announces Early Positive IMX-110 Interim Clinical Trial Data Demonstrating 100% Tumor Shrinkage in Advanced Metastatic Colorectal Cancer at the Lowest Dose of IMX-110 + BeiGene / Novartis Anti-PD-1 Antibody Tislelizumab - Vimarsana News

Immix Biopharma Announces Early Positive IMX-110 Interim Clinical Trial Data Demonstrating 100% Tumor Shrinkage in Advanced Metastatic Colorectal Cancer at the Lowest Dose of IMX-110 + BeiGene / Novartis Anti-PD-1 Antibody Tislelizumab

100% Tumor Shrinkage at 2-months in advanced metastatic colorectal cancer was demonstrated by IMX-110 + BeiGene / Novartis anti-PD-1 Antibody Tislelizumab combination in the first, lowest dose cohort ... | May 3, 2023